Skip to content

Existing Partnerships

Our versatile proprietary DeliverEXTM platform, rare disease-centred pipeline coupled with our dominant IP estate allow for broad multifaceted commercialization across a range of drug modalities and disease areas.

In light of the versatility of engineered exosome therapeutics, we view partnering as a crucial part of our pipeline-driven platform strategy. By collaboration with strategic partners and working together alongside their areas of expertise we can further harness the potential of therapeutic exosomes. 

Takeda Research Collaboration and License Agreement – Rare Diseases

In March 2020, Evox entered into a transformative research collaboration and licensing agreement with Takeda. The collaboration is a five-target rare disease-focused deal, centred on our protein replacement approach in disease settings. The initial programs include Niemann-Pick Type C1 and an undisclosed rare disease.

Lilly Research Collaboration and License Agreement - Neurology

In June 2020, we signed a second transformative research collaboration and license agreement with Lilly. This 4-year, undisclosed five-target partnership is focused on targeted exosome-mediated delivery of siRNA to the central nervous system for the treatment of neurodegenerative diseases.